Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
Terminated · Phase 2 · NCT04680975
Conditions: Diffuse Cutaneous Systemic Sclerosis
At a glance
- Research payments reported, 2025
- $17,270
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Kadmon, a Sanofi Company
- Tested
- Belumosudil (drug)
- Dates
- Started 2021-03-03; completion 2022-12-19
- Results posted
- Yes
This was a phase 2, open-label, single-cohort, multicenter trial of belumosudil in participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 participants would receive belumosudil 200 milligrams (mg) administered orally (PO) twice daily (BID) for 52 weeks. The primary analysis was at 24 weeks.
From ClinicalTrials.gov, last updated 2023-06-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $17,270 in research payments for this study in 2025 (1 payments).
Products named: Rezurock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.